In Q4 2025, Rock Springs Capital held 89 positions worth $1.8B. They initiated 12 new positions and exited 74. Their largest holding was LLY ($113.3M). Portfolio value grew +16.4% versus the prior quarter.
Frequently asked questions
What stocks did Rock Springs Capital own in Q4 2025?
Rock Springs Capital held 89 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include LLY, RVMD, ARGX, TVTX, MDGL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Rock Springs Capital's portfolio worth in Q4 2025?
Rock Springs Capital's tracked biotech portfolio was worth $1.8B across 89 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Rock Springs Capital buy in Q4 2025?
Rock Springs Capital initiated 12 new positions in Q4 2025, including IMNM, PTCT, TERN, RCUS, TBPH and 7 more. They also increased 34 existing positions.
What did Rock Springs Capital sell in Q4 2025?
Rock Springs Capital fully exited 74 positions in Q4 2025, including SPRO, FATE, DSGN, CRVO, WRBY and 69 more. They also trimmed 25 existing positions.
Is Rock Springs Capital a biotech fund?
Concentrated long/short healthcare fund focused on fundamental research. Rock Springs takes conviction-weighted positions based on deep pipeline analysis, therapeutic area expertise, and a willingness to be contrarian when the science supports it.
Want AI analysis, insider signals, and catalyst overlays for Rock Springs Capital?
View latest Rock Springs Capitalportfolio →